Costs are stratified by CD4+ count at ART initiation, and include costs of diagnostic testing, ART provision, treatment of opportunistic infections, outpatient visits, and inpatient days.
Introduction Chronic kidney disease (CKD) is a global health concern which results in significant economic burden. Despite this, treatment options are limited. Recently, dapagliflozin has been reporte
